TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11023477

Group type: EXPERIMENTAL
Intervention: GM‐CSF (sargramostim) 125 microgram/m(2) subcutaneously twice weekly for 6 months
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: GM‐CSF (sargramostim)
Number of subjects: 105
Study: 9291767

Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway
Number of subjects: 50
Study: 8228207

Group type: EXPERIMENTAL
Intervention: Ro 42‐5892 (600 mg orally, once a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Enalapril (20 mg orally, once a day)
Number of subjects: 8
Study: 3079482

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2645889

Group type: EXPERIMENTAL
Intervention: Nalmefene, 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone, 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline, 1.0 mL
Number of subjects: 0
Study: 31894045

Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride ointment
Number of subjects: 180

Group type: COMPARATOR
Intervention: 10% iodine
Number of subjects: 180
Study: 29050998

Group type: EXPERIMENTAL
Intervention: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (SAL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Methadone (0.2 mg kg−1) alone (MET)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Detomidine (5 μg kg−1) alone (DET)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Detomidine (2.5 μg kg−1) with methadone (0.2 mg kg−1) (MLD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Detomidine (5 μg kg−1) with methadone (0.2 mg kg−1) (MMD)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Detomidine (10 μg kg−1) with methadone (0.2 mg kg−1) (MHD)
Number of subjects: 8
Study: 25985940

Group type: EXPERIMENTAL
Intervention: Hand-held echocardiography (HHE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard echocardiography
Number of subjects: 100
Study: 24107879

Group type: EXPERIMENTAL
Intervention: Adaptol, 1500 mg daily divided into three doses for 8 weeks
Number of subjects: 62
Study: 21300344

Group type: EXPERIMENTAL
Intervention: Anastrozole at 1 mg/d
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Anastrozole at 5 mg/d
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Anastrozole at 10 mg/d
Number of subjects: 271

Group type: COMPARATOR
Intervention: Clomiphene citrate at 50 mg/d
Number of subjects: 271
Study: 20209968

Group type: EXPERIMENTAL
Intervention: Xianling Gubao capsules
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo of starch capsules
Number of subjects: 110
Study: 17009251

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogens (estrogen-alone trial)
Number of subjects: 26321

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate (estrogen-plus-progestin trial)
Number of subjects: 26321

Group type: COMPARATOR
Intervention: Placebo (for both trials)
Number of subjects: 26321
Study: 15504193

Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg kg(‐1) administered intravenously 3 min before induction of anaesthesia.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline administered intravenously 3 min before induction of anaesthesia (Control Group II).
Number of subjects: 50
Study: 10940063

Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 96

Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 96
Study: 9497795

Group type: COMPARATOR
Intervention: Normoglycaemia (blood glucose 5 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute hyperglycaemia (aimed at 15 mmol/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrajejunal fat administration (1 g/h) during normoglycaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrajejunal fat administration (1 g/h) during hyperglycaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia
Number of subjects: 0
Study: 7678184

Group type: EXPERIMENTAL
Intervention: TOAST classification system
Number of subjects: 20
Study: 3745847

Group type: EXPERIMENTAL
Intervention: Medium dose of liquid aluminum‐magnesium antacid (75 ml in five daily doses)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 78
Study: 29847553

Group type: EXPERIMENTAL
Intervention: Local sugar sweetened beverage health promotion and 20p price increase
Number of subjects: 0
Study: 27496239

Group type: EXPERIMENTAL
Intervention: Direct oral feeding (liquid oral diet for 2 weeks with gradually expanding daily maximums)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Delayed oral feeding (enteral feeding via jejunostomy for 5 days followed by liquid oral diet)
Number of subjects: 148
Study: 26016070

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (Toric‐IOL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Peripheral corneal relaxing incisions (PCRIs)
Number of subjects: 54
Study: 22541652

Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin) in intraocular infusion fluid (BSS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No enoxaparin (control group)
Number of subjects: 20
Study: 20228980

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel with carbopol as the thickening agent
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2% carbopol gel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide paste with poloxamer as the thickening agent
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Poloxamer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide strips for 21 days
Number of subjects: 45
Study: 18477382

Group type: EXPERIMENTAL
Intervention: Optic nerve sonography measurements in patients with severe brain injury (n=32)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Optic nerve sonography measurements in patients with moderate brain injury (n=18)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control individuals (n=26)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Correlation of ONSD with estimated ICP in severe brain injury patients
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Correlation of ONSD with neuroimaging scale results in severe brain injury patients
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Correlation of ONSD with invasive ICP values in severe brain injury patients
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cut-off value of ONSD for predicting elevated ICP in severe brain injury patients
Number of subjects: 76
Study: 16025151

Group type: EXPERIMENTAL
Intervention: Home care after ASCT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (hospital treatment)
Number of subjects: 90
Study: 12535290

Group type: EXPERIMENTAL
Intervention: Increased peritoneal clearance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard peritoneal clearance)
Number of subjects: 0
Study: 10694766

Group type: EXPERIMENTAL
Intervention: Tofu diet (290 g/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lean meat diet (150 g/d)
Number of subjects: 42
Study: 9339181

Group type: EXPERIMENTAL
Intervention: OND+MPS (ondansetron 8 mg po before chemotherapy, methylprednisolone 120 mg IV before chemotherapy, followed by ondansetron 8 mg po and methylprednisolone 16 mg po on days 1-4)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: OND+MPS
Number of subjects: 364

Group type: COMPARATOR
Intervention: TH (conventional antiemetic treatment: benzamide plus corticosteroids with or without benzodiazepines)
Number of subjects: 364

Group type: COMPARATOR
Intervention: TH
Number of subjects: 364
Study: 8368408

Group type: EXPERIMENTAL
Intervention: Oral postoperative corticosteroids
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (sugar pill)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (corticosteroids and placebo)
Number of subjects: 62
Study: 3521858

Group type: EXPERIMENTAL
Intervention: imidazole.2-hydroxybenzoate
Number of subjects: 30

Group type: COMPARATOR
Intervention: sulindac
Number of subjects: 30
Study: 31801052

Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) as adjunctive therapy
Number of subjects: 81
Study: 31067190

Group type: EXPERIMENTAL
Intervention: Self-monitoring plus telemonitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27793960

Group type: EXPERIMENTAL
Intervention: cabozantinib 60 mg orally once daily
Number of subjects: 658

Group type: COMPARATOR
Intervention: everolimus 10 mg orally once daily
Number of subjects: 658
Study: 25287751

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist liraglutide (1.2 mg per day)
Number of subjects: 52
Study: 23297810

Group type: EXPERIMENTAL
Intervention: Antidepressant cessation advice given to general practitioners in cases of overtreatment.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group with no specific information given to general practitioners.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 45
Study: 21654093

Group type: EXPERIMENTAL
Intervention: Hip strengthening prior to functional exercises
Number of subjects: 33

Group type: COMPARATOR
Intervention: Quadriceps strengthening prior to functional exercises
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 18266551

Group type: EXPERIMENTAL
Intervention: alcohol + anxiety induction (n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo + anxiety induction (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: alcohol + no anxiety induction (n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo + no anxiety induction (n = 20)
Number of subjects: 80
Study: 17191734

Group type: EXPERIMENTAL
Intervention: Mechanical conditioning at 25% Hmax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical conditioning at 50% Hmax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical conditioning at Hmax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical conditioning at 25% Hmax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical conditioning at 50% Hmax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical conditioning at Hmax
Number of subjects: 0
Study: 12709636

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 10978397

Group type: EXPERIMENTAL
Intervention: Guideline group
Number of subjects: 829

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 829
Study: 8927668

Group type: EXPERIMENTAL
Intervention: Continuation treatment with full doses of clomipramine, fluoxetine, or fluvoxamine
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Continuation treatment with half doses of clomipramine, fluoxetine, or fluvoxamine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Discontinuation of pharmacotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Withdrawal from drug therapy (three subgroups)
Number of subjects: 130
Study: 1839133

Group type: EXPERIMENTAL
Intervention: Conventional angioplasty
Number of subjects: 68

Group type: COMPARATOR
Intervention: Laser thermal angioplasty
Number of subjects: 68
Study: 6847173

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 300 mg/day
Number of subjects: 248

Group type: COMPARATOR
Intervention: Rimantadine hydrochloride 300 mg/day
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 200 mg/day
Number of subjects: 248

Group type: COMPARATOR
Intervention: Rimantadine hydrochloride 200 mg/day
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 248

Group type: COMPARATOR
Intervention: Rimantadine hydrochloride
Number of subjects: 248
Study: 30871894

Group type: EXPERIMENTAL
Intervention: Daily physiotherapy (mobilization, ambulation, shoulder exercises, breathing exercises)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no physiotherapy treatment)
Number of subjects: 94
Study: 30311724

Group type: EXPERIMENTAL
Intervention: 1.5% olive ointment (n = 37)
Number of subjects: 73

Group type: COMPARATOR
Intervention: 1.5% calendula ointment (n = 39)
Number of subjects: 73
Study: 26071866

Group type: EXPERIMENTAL
Intervention: Peripheral blood grafts (PB)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group (nonparticipants)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Overall survival, transplantation-related mortality, and incidences of acute or chronic graft-versus-host disease
Number of subjects: 494
Study: 24350748

Group type: EXPERIMENTAL
Intervention: Peer-led, asynchronous, online support group
Number of subjects: 0
Study: 22307477

Group type: EXPERIMENTAL
Intervention: 750,000 IU/mo vitamin A supplementation
Number of subjects: 130

Group type: COMPARATOR
Intervention: No supplemental vitamin A (unsupplemented)
Number of subjects: 130
Study: 19614639

Group type: EXPERIMENTAL
Intervention: Pre‐AF group (30 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No‐AF group (60 patients)
Number of subjects: 90
Study: 17500048

Group type: EXPERIMENTAL
Intervention: 400 mg metformin and 2.5 mg glibenclamide per coated tablet (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15337557

Group type: EXPERIMENTAL
Intervention: Combined modality therapy for ST‐PNETs
Number of subjects: 44
Study: 12649946

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 I.U. for children > 12 months, 100,000 I.U. for children 6-12 months, 500,000 I.U. for children < 6 months) every 4 to 6 months for 15 months
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1520
Study: 9426014

Group type: EXPERIMENTAL
Intervention: Abciximab bolus and infusion
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Abciximab bolus alone
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study: 8752612

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily for 6 months)
Number of subjects: 25
Study: 2331204

Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback/Protocol
Number of subjects: 0
Study: 6932866

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 33
Study: 31248841

Group type: EXPERIMENTAL
Intervention: Duloxetine (30-120 mg daily; mean 92.1 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50-100 mg daily; mean 93.6 mg/day)
Number of subjects: 66
Study: 27510947

Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Screening intervention (effectiveness design)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Screening intervention (efficacy design)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Screening intervention (overall efficacy)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Screening intervention (pre-consent centres)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Screening intervention (post-consent centres)
Number of subjects: 6
Study: 26407981

Group type: EXPERIMENTAL
Intervention: Self-hypnosis intervention (two antenatal training sessions and a supporting CD)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Self-hypnosis intervention
Number of subjects: 343
Study: 24033696

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 709
Study: 22190133

Group type: EXPERIMENTAL
Intervention: 300,000 IU vitamin D3
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 150,000 IU vitamin D3
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20234305

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Interactive seminar
Number of subjects: 20
Study: 17573445

Group type: EXPERIMENTAL
Intervention: Papworth method (5 sessions)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 85
Study: 15459518

Group type: EXPERIMENTAL
Intervention: Physical therapy program (Kegel exercises and interferential current) for 5 weeks, 15 sessions
Number of subjects: 48
Study: 12440556

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blockers (general)
Number of subjects: 0
Study: 9606617

Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flutamide 250 mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Castration
Number of subjects: 0
Study: 8562104

Group type: EXPERIMENTAL
Intervention: Group A (rewarmed by a new device that acts by both conduction and convection)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (covered with cotton blankets)
Number of subjects: 30
Study: 2368889

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone 4 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 324257

Group type: EXPERIMENTAL
Intervention: Minoxidil (average dose 19.7 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30407567

Group type: EXPERIMENTAL
Intervention: Muscimol infusion
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Standard epilepsy surgery
Number of subjects: 3
Study: 28760058

Group type: EXPERIMENTAL
Intervention: Video information in addition to the regular information leaflet
Number of subjects: 136

Group type: COMPARATOR
Intervention: Regular information leaflet (Control)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Video information
Number of subjects: 136
Study: 25283350

Group type: EXPERIMENTAL
Intervention: Real rTMS plus mCIMT (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham rTMS plus mCIMT (n = 9)
Number of subjects: 19
Study: 24171300

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream, applied twice a day for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus 0.03% cream, applied twice a day for 4 weeks
Number of subjects: 60
Study: 21737767

Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg sustained-release once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19031231

Group type: EXPERIMENTAL
Intervention: Suggestion to become a same-sex sibling; administered 2 challenges to the temporary delusion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggestion to become someone similar or dissimilar to themselves (Experiment 1).
Number of subjects: 0
Study: 16671518

Group type: EXPERIMENTAL
Intervention: Comprehensive perioperative management (Group B, 226 patients)
Number of subjects: 258

Group type: COMPARATOR
Intervention: No comprehensive perioperative management (Group A, 32 patients)
Number of subjects: 258
Study: 15591456

Group type: EXPERIMENTAL
Intervention: Sialyl Lewis(a) expression levels
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 233
Study: 11689036

Group type: EXPERIMENTAL
Intervention: Target game (repeated participation)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Target game (single participation)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Age group (7-year-olds)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Age group (4-year-olds)
Number of subjects: 2
Study: 9383779

Group type: EXPERIMENTAL
Intervention: High-meat diet (600 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-meat diet (40 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-meat diet (600 g) with resistant starch (37 g)
Number of subjects: 8
Study: 8936955

Group type: EXPERIMENTAL
Intervention: Recombinant Interferon-2b (IFN-2b) at a dose of 5 MU/m2 three times a week, subcutaneously for 6 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 12
Study: 2782648

Group type: COMPARATOR
Intervention: Pediatric circle system at FGF of 0.5 x VE (C0.5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pediatric circle system at FGF of 1.5 x VE (C1.5)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jackson-Rees system at FGF of 1.5 x VE (JR1.5)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jackson-Rees system at FGF of 3.0 x VE (JR3.0)
Number of subjects: 11
Study: 128937

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (initially injected + Butazolidin Alka p.o.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31394912

Group type: EXPERIMENTAL
Intervention: Problematic smartphone use (PSU) assessed by the Smartphone Addiction Scale‐Short Version
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Perceived family communication sufficiency
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Perceived family communication quality
Number of subjects: 5063
Study: 28679529

Group type: EXPERIMENTAL
Intervention: 50% of daily calories consumed at breakfast (BF group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50% of daily calories consumed at dinner (D group)
Number of subjects: 0
Study: 26545535

Group type: EXPERIMENTAL
Intervention: Immunomodulatory enteral nutrition
Number of subjects: 29

Group type: COMPARATOR
Intervention: High ω3 enteral nutrition
Number of subjects: 29
Study: 23787719

Group type: EXPERIMENTAL
Intervention: Individualized salt and fluid restriction (1.5 L fluid and 5 g salt daily) with dietary advice and support
Number of subjects: 97

Group type: COMPARATOR
Intervention: Information given by nurse-led heart failure clinics (control group)
Number of subjects: 97
Study: 20930017

Group type: EXPERIMENTAL
Intervention: Summary KS1 data
Number of subjects: 3394

Group type: EXPERIMENTAL
Intervention: Individual question scores
Number of subjects: 3394